ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1661

Sex-Stratified Patterns of Multimorbidity at RA Onset and Associated Longitudinal Impacts on Disability Over the First Year Follow Up: Results from the Canadian Early Arthritis Cohort (CATCH)

Orit Schieir1, Susan Bartlett2, Marie-France Valois2, Louis Bessette3, Gilles Boire4, Glen Hazlewood5, Edward Keystone6, Janet Pope7, Carter Thorne8, Diane Tin8 and Vivian Bykerk9, 1Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, 2McGill University, Montréal, QC, Canada, 3Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 4Universite de Sherbrooke, Sherbrooke, QC, Canada, 5University of Calgary, Calgary, AB, Canada, 6Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 7University of Western Ontario, London, ON, Canada, 8Southlake Regional Health Centre, Newmarket, ON, Canada, 9Division of Rheumatology, Hospital for Special Surgery, New York City, NY

Meeting: ACR Convergence 2021

Keywords: Cohort Study, Disability, multimorbidity, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: RA – Diagnosis, Manifestations, & Outcomes Poster IV: Outcomes, Trajectory of Disease, & Epidemiology (1645–1673)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Chronic disease multimorbidity (MM) is prevalent in RA. As MM can vary in complexity and different combinations of chronic conditions may have different physical and psychological impacts on patients, there is an increasing need to identify which specific conditions may cluster around the time of RA onset. The objective of the present study was to identify the top 10 most prevalent MC patterns in women and men around RA diagnosis and estimate their associations with disability over the first year of follow up, in a large real-world incident RA cohort.

Methods: Data were from early RA patients (< 1-year of symptoms; 88% meeting RA classification criteria) diagnosed and treated in rheumatology clinics across Canada enrolled in CATCH (Canadian Early Arthritis Cohort) from Jan 2007 through March 2020. Participants were included in the present study if they completed the Rheumatic Disease Comorbidity Index (RDCI) at baseline and repeat assessments of disease activity (DAS28) and disability (MHAQ) every 3- months over 1 year follow up. The RDCI is a validated weighted comorbidity index (range 0-9) assessing the presence of 11 conditions selected based on associations with RD health outcomes (lung disease, CVD (MI, stroke, and other CV), HTN, fracture, depression, diabetes, cancer, ulcer or stomach problem). We identified the top 10 most prevalent MM patterns in women and men by first coding the presence/ absence of each condition for each participant and then ranking the prevalence of all possible reported combinations by sex. We estimated sex-stratified longitudinal associations between prevalent MM patterns and repeated measures of disability in the first year follow up with generalized estimating equations (GEE), adjusted for age, education, symptom duration, smoking, obesity and time-varying measures of DAS28 disease activity.

Results: The sample included 2,576 ERA patients, 1843 (72%) were female, with a mean(sd) age of 56 (15) years and 6 (3) months of symptoms. At baseline 2,449 (95%) were treated with csDMARDs (mostly methotrexate (74%)) and 40 (2%) with a biologic. More than half of patients (54%) reported >=1 MM. Prevalence, patterns and complexity of MM differed by sex. HTN, lung disease and depression were the most prevalent MM patterns reported in women and HTN, CVD, and CVD+HTN were the most prevalent patterns reported in men (Figure). More complex MM patterns involving multiple conditions were more prevalent in men (26%) than in women (12%) (Figure). In multivariable GEE models, depression (beta: 0.14, 95% CI: 0.04, 0.24) in women, and lung disease + HTN (beta: 0.22, 95% CI: 0.03, 0.42) in men, were significantly associated with higher disability over time.

Conclusion: Results from this large real-world incident cohort study suggest that multimorbidity is common around RA diagnosis and differs between men and women. MM patterns significantly associated with increased disability over time included depression in women, and lung disease + HTN in men. Results suggest potential shared risk factors and pathways between identified MM patterns and highlight the need to screen for and treat MM conditions, particularly those which increase disability.


Disclosures: O. Schieir, None; S. Bartlett, Merck Canada, 2, 6, Pfizer Canada, 2, 6, Janssen Canada, 2, 6, PROMIS Health Organization, 4, American Thoracic Society, 4, Arthritis Health Professionals Association, 4, UCB, 1, RAND Corporation, 1; M. Valois, None; L. Bessette, Amgen, 2, 5, 6, Bristol-Myers Squibb, 2, 5, 6, Janssen, 2, 5, 6, Roche, 2, 5, 6, UCB, 2, 5, 6, AbbVie, 2, 5, 6, Pfizer, 2, 5, 6, Merck & Co, 2, 5, Celgene, 2, 5, 6, Sanofi, 2, 5, 6, Eli Lilly, 2, 5, 6, Novartis, 2, 5, 6, Gilead, 2, 5, 6, Sandoz, 2, 5, 6, Teva, 2, 6; G. Boire, Abbvie, 1, 6, 7, BMS, 6, 7, Janssen, 1, 5, 6, Eli Lilly, 1, 7, Amgen, 7, Novartis, 6, 7, Pfizer, 7, Sandoz, 6, 7, Viatris, 1, 6, Samsung Bioepis, 1; G. Hazlewood, None; E. Keystone, AbbVie, 2, 6, Amgen, 2, 5, 6, Bristol-Myers Squibb Company, 2, Celltrion, 2, Gilead Sciences, 2, F. Hoffmann-La Roche, 2, 6, Janssen, 2, 6, Eli Lilly, 2, Merck, 2, 5, 6, Myriad Autoimmune, 2, Novartis, 6, Pfizer Inc, 2, 5, 6, PuraPharm, 5, Sandoz, 2, Sanofi-Genzyme, 2, 6, Samsung Bioepis, 2; J. Pope, AbbVie, 2, Amgen, 2, Bayer, 2, Bristol-Myers Squibb, 2, 5, Eli Lilly, 2, Merck, 2, Novartis, 2, Pfizer Inc, 2, Roche, 2, 5, Sanofi, 2, Seattle Genetics, 5, UCB, 2, 5, Actelion, 2, Sandoz, 2; C. Thorne, AbbVie, 1, Amgen Inc, 1, Celgene, 1, Eli Lilly, 1, Medexus/Medac, 1, 2, 6, Merck, 1, 2, Novartis, 1, 5, Pfizer, 1, 5, Sandoz, 1, Sanofi, 1, Centocor, 2; D. Tin, None; V. Bykerk, National Institutes of Health, 1, 5, Canadian Institutes of Health Research, 5, Amgen, 2, 5, BMS, Celgene, 2, 6, Gilead, 2, Sanofi, 2, 6, Regeneron, 2, Eli Lilly and Company, 6, Pfizer, 6, UCB, 6.

To cite this abstract in AMA style:

Schieir O, Bartlett S, Valois M, Bessette L, Boire G, Hazlewood G, Keystone E, Pope J, Thorne C, Tin D, Bykerk V. Sex-Stratified Patterns of Multimorbidity at RA Onset and Associated Longitudinal Impacts on Disability Over the First Year Follow Up: Results from the Canadian Early Arthritis Cohort (CATCH) [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/sex-stratified-patterns-of-multimorbidity-at-ra-onset-and-associated-longitudinal-impacts-on-disability-over-the-first-year-follow-up-results-from-the-canadian-early-arthritis-cohort-catch/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sex-stratified-patterns-of-multimorbidity-at-ra-onset-and-associated-longitudinal-impacts-on-disability-over-the-first-year-follow-up-results-from-the-canadian-early-arthritis-cohort-catch/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology